GlobeImmune to present an abstract of GI-5005 drug at AASLD's annual meeting

GlobeImmune Inc. today announced that a late breaking abstract related to GI-5005, its investigational hepatitis C virus (HCV) product candidate, has been accepted for presentation at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place Oct. 31 through Nov. 4, 2009, in Boston, Mass.

The abstract, titled "GI-5005 Therapeutic Vaccine Plus PEG-IFN/Ribavirin Improves End of Treatment Response at 48 Weeks Versus PEG-IFN/Ribavirin in Naïve Genotype 1 Chronic HCV Patients," is published online at the AASLD website (www.aasld.org).

At the AASLD meeting, GlobeImmune will present end-of-treatment, 48-week data in interferon-naïve patients from a Phase 2 clinical study investigating the efficacy and safety of GI-5005 plus peg-interferon (peg-IFN) and ribavirin, the current standard of care (SOC), in patients with genotype 1 chronic HCV infection compared to patients receiving only SOC.

Dr. John G. McHutchison, associate director of the Duke Clinical Research Institute at Duke University Medical Center, is the lead author of the abstract that will be presented as part of a late breaking poster session beginning at 8 a.m. EST on Monday, Nov. 2, 2009. The presentation will include complete response rates and ALT data for patients who completed 48 weeks of triple therapy, as well as SOC patients in the control arm of the study.

GI-5005 is a therapeutic vaccine product candidate that contains conserved HCV proteins and is designed to generate HCV specific T-cell responses in both the pre-clinical and clinical setting.

Source:

GlobeImmune, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI algorithm accurately detects early-stage metabolic-associated steatotic liver disease